ClinicalTrials.gg
CompletedNCT02532855Updated Nov 20, 2018Results posted

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

A Phase 3 interventional study of Sitagliptin and Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2018-11-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
25 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
22nd of 197
614 · median 102
Started
2015
with 12 others
Phase 3
74 of 198
none open now
Registered
161st of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2015, is one of 74 in phase 3, and was the 161st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 25 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to assess the effect of the addition of sitagliptin to metformin with or without a sulfonylurea compared with the addition of dapagliflozin to metformin with or without a sulfonylurea on hemoglobin A1c (A1C) over 24 weeks of treatment as well as the overall safety and tolerability of sitagliptin in comparison to that of dapagliflozin after 24 weeks of treatment. The primary hypothesis is that the change from baseline in A1C in participants treated with the addition of sitagliptin is non-inferior compared to that in participants treated with the addition of dapagliflozin after 24 weeks of treatment.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have T2DM at Screening visit
  • Be on metformin monotherapy ≥1500 mg/day alone or in combination with an sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the site) for ≥8 weeks
  • Is a male or a female not of (defined as one who is or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening visit). If participant is a female of reproductive potential, must agree to remain abstinent from heterosexual activity or agrees to use (or have her partner use) acceptable to prevent pregnancy while receiving blinded study drug and for 14 days after the last dose of blinded study drug

Exclusion criteria

Exclusion Criteria:

  • Has a history of type 1 diabetes mellitus or a history of ketoacidosis
  • Has a history of secondary causes of diabetes
  • Has a known or intolerance to any dipeptidyl peptidase IV (DPP-4) inhibitor or sodium-glucose cotransporter 2 (SGLT2) inhibitor
  • Has been treated with any anti-hyperglycemic agents (AHA) other than metformin and for participants on dual combination therapy, a sulfonylurea within 12 weeks of screening
  • Intends to initiate weight loss medication during the study period
  • Has undergone bariatric surgery within 12 months of Screening visit
  • Has started a weight loss medication or a medication associated with weight changes within the prior 12 weeks.
  • Has a history of myocardial infarction, unstable angina, arterial revascularization, stroke, , heart failure within 3 months of Screening visit
  • Has a history of ≤5 years prior to study, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • Has (HIV)
  • Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells, or hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • Has a medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic or C, primary biliary cirrhosis, or symptomatic gallbladder disease
  • Is currently being treated for hyperthyroidism or is on thyroid replacement therapy and has not been on a stable dose for at least 6 weeks prior to Screening visit
  • Is on or likely to require treatment for ≥14 consecutive days or repeated courses of
  • Is on or likely to require treatment for ≥7 consecutive days with non-steroidal anti-inflammatory drugs
  • Is pregnant or breast-feeding, or is planning to conceive during the study, including 14 days following the last dose of blinded study drug
  • Is planning to undergo hormonal therapy in preparation to donate eggs during the study, including 14 days following the last dose of blinded study drug
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or engages in binge drinking
  • Has donated blood or blood products within 6 weeks of Screening visit or who plans to donate blood or blood products at any time during the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.

    Drug: Sitagliptin · Drug: Metformin · Drug: Matching placebo to dapagliflozin · Drug: Sulfonylurea

  • Active comparator
    Dapagliflozin

    Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.

    Drug: Dapagliflozin · Drug: Metformin · Drug: Matching placebo to sitagliptin · Drug: Sulfonylurea

Interventions

  • Sitagliptin 100 mg oral tablet

  • Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.

  • This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.

  • DrugMatching placebo to sitagliptin

    Matching placebo to sitagliptin 100 mg oral tablet

  • DrugMatching placebo to dapagliflozin

    Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.

  • DrugSulfonylurea

    Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea

    This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 24

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 24 A1C minus the Week 0 A1C.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Who Experienced One or More Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product. The AE does not have to have a causal relationship with this treatment. The AE can include any unfavourable and unintended sign, symptom, or disease or any worsening (change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the pharmaceutical product.

    Time frame: Up to 26 weeks

  3. Percentage of Participants Who Discontinued Study Drug Due to an AE

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product. The AE does not have to have a causal relationship with this treatment. The AE can include any unfavourable and unintended sign, symptom, or disease or any worsening (change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the pharmaceutical product.

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Change From Baseline in Incremental 2-hour (2-hr) Postprandial Glucose Excursion (PPGE) at Week 24

    The 2hr PPGE is the change from baseline in the mean incremental change in post meal glucose defined as T-120 minus T-0 for each participant: change from baseline PPGE = Week 24 mean (T-120 minus T-0) minus Baseline mean (T-120 minus T-0). The 2-point MMTT measured values at T-0 and T-120 while the 3-point MMTT measured values at T-0, T-60, and T-120: although only a subset of the study had the 3-point MMTT performed, all participants had a T-0 and T-120 time point. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

    Time frame: Immediately before and 120 minutes after the standard meal at Baseline and Week 24

  2. Change From Baseline in 2-hr Postprandial Glucose (PPG) at Week 24

    The 2hr PPG is the change from baseline in mean post prandial glucose (change from baseline PPG = Week 24 mean T-120 glucose minus Baseline mean T-120 glucose) and shows each drugs impact on PPG. The 2-point MMTT measured values at T-0 and T-120 while the 3-point MMTT measured values at T-0, T-60, and T-120: although only a subset of the study had the 3-point MMTT performed, all participants had a T-0 and T-120 time point. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

    Time frame: Immediately before and 120 minutes after the standard meal at Baseline and Week 24

  3. Change From Baseline in Glucagon Area Under the Curve (AUC0-120 Minutes) at Week 24

    AUC endpoints were analyzed for participants who underwent the 3-point MMTT. Blood samples were drawn immediately prior to (T=0 minutes) and 60 and 120 minutes after the administration of the standard meal. The AUC curve was generated with the 3 time points. If any time point for a given participant was missing, the AUC was not included. Change in Postprandial Glucagon AUC after the morning meal (t=0 to 120 minutes) was calculated from the glucagon AUC over the first 120 minutes following the morning meal at baseline minus glucagon AUC over the first 120 minutes following the morning meal at Week 24. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

    Time frame: Immediately before and 60 and 120 minutes after the standard meal at Baseline and Week 24

  4. Change From Baseline in Insulin AUC0-120 Minutes at Week 24

    AUC endpoints were analyzed for participants who underwent the 3-point MMTT. Blood samples were drawn immediately prior to (T=0 minutes) and 60 and 120 minutes after the administration of the standard meal. The AUC curve was generated with the 3 time points. If any time point for a given participant was missing, the AUC was not included. Change in Postprandial Insulin AUC after the morning meal (t=0 to 120 minutes) was calculated from insulin AUC over the first 120 minutes following the morning meal at baseline minus insulin AUC over the first 120 minutes following the morning meal at Week 24. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

    Time frame: Immediately before and 60 and 120 minutes after the standard meal at Baseline and Week 24

  5. Change From Baseline in Postprandial Insulin AUC0-120 Minutes to Glucagon AUC0-120 Minutes Ratio at Week 24

    AUC endpoints were analyzed for participants who underwent the 3-point MMTT. Blood samples were drawn immediately prior to (T=0 minutes) and 60 and 120 minutes after the administration of the standard meal. The AUC curve was generated with the 3 time points. If any time point for a given participant was missing, the AUC was not included. The endpoint was calculated from the ratio of (insulin AUC / glucagon AUC) over the first 120 minutes following the morning meal at baseline minus AUC over the first 120 minutes following the morning meal at Week 24. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

    Time frame: Immediately before and 60 and 120 minutes after the standard meal at Baseline and Week 24

  6. Percentage of Participants With A1C <7% (53 mmol/Mol) at Week 24

    A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

    Time frame: Week 24

  7. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at Week 0).

    Time frame: Baseline and Week 24

07

Results

Posted Oct 10, 2018

Participant flow

This study was conducted at 183 medical centers in 24 countries.

Participant flow — Overall Study
MilestoneSitagliptinDapagliflozin
Started307307
Treated307306
Completed299296
Not completed811
Withdrew: Lost to follow-up43
Withdrew: Withdrawal by subject48

Outcome measures

PrimaryChange From Baseline in A1C at Week 24

A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 24 A1C minus the Week 0 A1C.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent A1C
Change From Baseline in A1C at Week 24
Percent A1CSitagliptinDapagliflozin
Change From Baseline in A1C at Week 24-0.51 (-0.60 to -0.43)-0.36 (-0.45 to -0.27)
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in lsm (sit. - dap.): -0.15 · 95% CI -0.26 to -0.04LDA model including terms for treatment, time, background AHA, the interaction of time and background AHA, and the interaction of time by treatment.
  • Sitagliptin vs Dapagliflozin · Longitudinal data analysis · p = 0.006 · Difference in lsm (sit. - dap.): -0.15 · 95% CI -0.26 to -0.04LDA model including terms for treatment, time, background AHA, the interaction of time and background AHA, and the interaction of time by treatment.
PrimaryPercentage of Participants Who Experienced One or More Adverse Events

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product. The AE does not have to have a causal relationship with this treatment. The AE can include any unfavourable and unintended sign, symptom, or disease or any worsening (change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the pharmaceutical product.

Time frame:
Up to 26 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced One or More Adverse Events
Percentage of participantsSitagliptinDapagliflozin
Percentage of Participants Who Experienced One or More Adverse Events48.951.6
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in % (sit. - dap.): -2.8 · 95% CI -10.7 to 5.1Miettinen \& Nurminen method
PrimaryPercentage of Participants Who Discontinued Study Drug Due to an AE

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product. The AE does not have to have a causal relationship with this treatment. The AE can include any unfavourable and unintended sign, symptom, or disease or any worsening (change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the pharmaceutical product.

Time frame:
Up to 24 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Drug Due to an AE
Percentage of participantsSitagliptinDapagliflozin
Percentage of Participants Who Discontinued Study Drug Due to an AE3.33.3
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in % (sit. - dap.): -0.0 · 95% CI -3.0 to 3.0Miettinen \& Nurminen method
SecondaryChange From Baseline in Incremental 2-hour (2-hr) Postprandial Glucose Excursion (PPGE) at Week 24

The 2hr PPGE is the change from baseline in the mean incremental change in post meal glucose defined as T-120 minus T-0 for each participant: change from baseline PPGE = Week 24 mean (T-120 minus T-0) minus Baseline mean (T-120 minus T-0). The 2-point MMTT measured values at T-0 and T-120 while the 3-point MMTT measured values at T-0, T-60, and T-120: although only a subset of the study had the 3-point MMTT performed, all participants had a T-0 and T-120 time point. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

Time frame:
Immediately before and 120 minutes after the standard meal at Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Incremental 2-hour (2-hr) Postprandial Glucose Excursion (PPGE) at Week 24
mg/dLSitagliptinDapagliflozin
Change From Baseline in Incremental 2-hour (2-hr) Postprandial Glucose Excursion (PPGE) at Week 24-24.2 (-30.4 to -18.0)-18.5 (-24.9 to -12.1)
Statistical analysis
  • Sitagliptin vs Dapagliflozin · LDA · p = 0.138 · Difference in lsm (sit. - dap.): -5.7 · 95% CI -13.3 to 1.8LDA model including terms for treatment, time, background AHA, the interaction of time and background AHA, and the interaction of time by treatment.
SecondaryChange From Baseline in 2-hr Postprandial Glucose (PPG) at Week 24

The 2hr PPG is the change from baseline in mean post prandial glucose (change from baseline PPG = Week 24 mean T-120 glucose minus Baseline mean T-120 glucose) and shows each drugs impact on PPG. The 2-point MMTT measured values at T-0 and T-120 while the 3-point MMTT measured values at T-0, T-60, and T-120: although only a subset of the study had the 3-point MMTT performed, all participants had a T-0 and T-120 time point. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

Time frame:
Immediately before and 120 minutes after the standard meal at Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-hr Postprandial Glucose (PPG) at Week 24
mg/dLSitagliptinDapagliflozin
Change From Baseline in 2-hr Postprandial Glucose (PPG) at Week 24-40.4 (-46.9 to -33.9)-37.0 (-43.7 to -30.3)
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in the lsm (sit. - dap.): -3.4 · 95% CI -12.1 to 5.3The ANCOVA model included terms for treatment, background AHA, and the baseline 2-hour PPG value as a covariate.
SecondaryChange From Baseline in Glucagon Area Under the Curve (AUC0-120 Minutes) at Week 24

AUC endpoints were analyzed for participants who underwent the 3-point MMTT. Blood samples were drawn immediately prior to (T=0 minutes) and 60 and 120 minutes after the administration of the standard meal. The AUC curve was generated with the 3 time points. If any time point for a given participant was missing, the AUC was not included. Change in Postprandial Glucagon AUC after the morning meal (t=0 to 120 minutes) was calculated from the glucagon AUC over the first 120 minutes following the morning meal at baseline minus glucagon AUC over the first 120 minutes following the morning meal at Week 24. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

Time frame:
Immediately before and 60 and 120 minutes after the standard meal at Baseline and Week 24
Reported as:
Least squares mean · pmol.hr/L
Change From Baseline in Glucagon Area Under the Curve (AUC0-120 Minutes) at Week 24
pmol.hr/LSitagliptinDapagliflozin
Change From Baseline in Glucagon Area Under the Curve (AUC0-120 Minutes) at Week 24-4.2 (-8.8 to 0.4)0.2 (-4.4 to 4.8)
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in the lsm (sit. - dap.): -4.4 · 95% CI -10.1 to 1.4The ANCOVA model included terms for treatment, background AHA, and the baseline glucagon AUC value as a covariate.
SecondaryChange From Baseline in Insulin AUC0-120 Minutes at Week 24

AUC endpoints were analyzed for participants who underwent the 3-point MMTT. Blood samples were drawn immediately prior to (T=0 minutes) and 60 and 120 minutes after the administration of the standard meal. The AUC curve was generated with the 3 time points. If any time point for a given participant was missing, the AUC was not included. Change in Postprandial Insulin AUC after the morning meal (t=0 to 120 minutes) was calculated from insulin AUC over the first 120 minutes following the morning meal at baseline minus insulin AUC over the first 120 minutes following the morning meal at Week 24. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

Time frame:
Immediately before and 60 and 120 minutes after the standard meal at Baseline and Week 24
Reported as:
Least squares mean · mIU.hr/L
Change From Baseline in Insulin AUC0-120 Minutes at Week 24
mIU.hr/LSitagliptinDapagliflozin
Change From Baseline in Insulin AUC0-120 Minutes at Week 24-23.4 (-36.8 to -9.9)-28.2 (-42.1 to -14.4)
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in the lsm (sit. - dap.): 4.9 · 95% CI -12.2 to 22.0The ANCOVA model included terms for treatment, background AHA, and the baseline insulin AUC value as a covariate.
SecondaryChange From Baseline in Postprandial Insulin AUC0-120 Minutes to Glucagon AUC0-120 Minutes Ratio at Week 24

AUC endpoints were analyzed for participants who underwent the 3-point MMTT. Blood samples were drawn immediately prior to (T=0 minutes) and 60 and 120 minutes after the administration of the standard meal. The AUC curve was generated with the 3 time points. If any time point for a given participant was missing, the AUC was not included. The endpoint was calculated from the ratio of (insulin AUC / glucagon AUC) over the first 120 minutes following the morning meal at baseline minus AUC over the first 120 minutes following the morning meal at Week 24. A negative (-) change from baseline to Week 24 indicates better control of postprandial glucose.

Time frame:
Immediately before and 60 and 120 minutes after the standard meal at Baseline and Week 24
Reported as:
Least squares mean · Ratio
Change From Baseline in Postprandial Insulin AUC0-120 Minutes to Glucagon AUC0-120 Minutes Ratio at Week 24
RatioSitagliptinDapagliflozin
Change From Baseline in Postprandial Insulin AUC0-120 Minutes to Glucagon AUC0-120 Minutes Ratio at Week 24-0.6 (-1.1 to -0.0)-1.2 (-1.8 to -0.7)
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in the lsm (sit. - dap.): 0.6 · 95% CI -0.1 to 1.3The ANCOVA model included terms for treatment, background AHA, and the baseline insulin AUC to glucagon AUC ratio value as a covariate.
SecondaryPercentage of Participants With A1C <7% (53 mmol/Mol) at Week 24

A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants With A1C <7% (53 mmol/Mol) at Week 24
Percentage of ParticipantsSitagliptinDapagliflozin
Percentage of Participants With A1C <7% (53 mmol/Mol) at Week 2442.627.0
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in % (sit. - dap.): 15.5 · 95% CI 7.7 to 23.2Miettinen and Nurminen (M\&N) method with multiple imputation from a LDA Model.
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 24 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 24 minus FPG at Week 0).

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/dLSitagliptinDapagliflozin
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-16.5 (-20.6 to -12.5)-20.1 (-24.3 to -15.9)
Statistical analysis
  • Sitagliptin vs Dapagliflozin · Difference in the lsm (sit. - dap.): 3.5 · 95% CI -1.2 to 8.3LDA model including terms for treatment, time, background AHA, the interaction of time and background AHA, and the interaction of time by treatment.

Adverse events

Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin0/307 (0%)10/307 (3.3%)22/307 (7.2%)
Dapagliflozin0/306 (0%)13/306 (4.2%)21/306 (6.9%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventSitagliptinDapagliflozin
Atrioventricular block second degreeCardiac disorders0/3071/306
Myocardial infarctionCardiac disorders0/3071/306
EnterocolitisGastrointestinal disorders0/3071/306
Pancreatitis acuteGastrointestinal disorders0/3071/306
Upper gastrointestinal haemorrhageGastrointestinal disorders0/3071/306
Non-cardiac chest painGeneral disorders0/3071/306
InfluenzaInfections and infestations0/3071/306
PneumoniaInfections and infestations0/3071/306
SepsisInfections and infestations0/3071/306
Femoral neck fractureInjury, poisoning and procedural complications1/3071/306
Most frequent other events
Most frequent other events
EventSitagliptinDapagliflozin
HypoglycaemiaMetabolism and nutrition disorders22/30721/306

Baseline characteristics

All randomized and treated participants

Age, Continuous
Age, Continuous(Years)SitagliptinDapagliflozinTotal
Mean67.7 ± 8.566.6 ± 8.667.1 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinDapagliflozinTotal
Female138120258
Male169186355
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SitagliptinDapagliflozinTotal
American Indian or Alaska Native181432
Asian11718
Native Hawaiian or Other Pacific Islander011
Black or African American81119
White240234474
More than one race303969
Unknown or Not Reported000
Hemoglobin A1C
Hemoglobin A1C(Percent A1C)SitagliptinDapagliflozinTotal
Mean7.7 ± 0.77.8 ± 0.77.7 ± 0.7
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)SitagliptinDapagliflozinTotal
Mean162.3 ± 40.4165.2 ± 40.6163.8 ± 40.5
Background Antihyperglycemic Agent (AHA)
Background Antihyperglycemic Agent (AHA)(Participants)SitagliptinDapagliflozinTotal
Metformin Alone212225437
Metformin and Sulfonylurea9581176
Incremental 2-hour Postprandial Glucose Excursion (PPGE)
Incremental 2-hour Postprandial Glucose Excursion (PPGE)(mg/dL)SitagliptinDapagliflozinTotal
Mean96.2 ± 55.395.7 ± 47.195.9 ± 51.4
2-hr Postprandial Glucose
2-hr Postprandial Glucose(mg/dL)SitagliptinDapagliflozinTotal
Mean257.7 ± 67.1259.9 ± 64.4258.8 ± 65.7

3 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018 Dec;20(12):2876-2884. doi: 10.1111/dom.13473. Epub 2018 Aug 16. PubMed 30019498 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Oct 2017, 23 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2015
First posted
Aug 26, 2015
StartActual
Oct 20, 2015
Primary completionActual
Oct 10, 2017
CompletionActual
Oct 10, 2017
Results first posted
Oct 10, 2018
Last update
Nov 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02532855
Responsible party
Sponsor
First posted
Aug 26, 2015
Start date
Oct 20, 2015
Primary completion
Oct 10, 2017
Completion
Oct 10, 2017
Results posted
Oct 10, 2018
Last update
Nov 20, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion